SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Nuveen Real Asset Income and Growth Fund (JRI) trades at a trailing P/E of 7.2. Trailing earnings yield is 13.89%. PEG 0.08 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (7.2); PEG ≤ 1.0 — Peter Lynch undervalued (0.08); earnings yield beats bond yields (13.89%).
- PEG Ratio 0.08 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 13.89% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 81/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — JRI
Valuation Multiples
P/E (TTM)7.2
Forward P/EN/A
PEG Ratio0.08
Forward PEGN/A
P/B Ratio0.00
P/S Ratio8.11
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.79
Book Value / Share$0.00
Revenue / Share$1.59
FCF / Share$0.00
Yields & Fair Value
Earnings Yield13.89%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.16 |
$15.9M |
$21.08M |
132.6% |
| 2017 |
$2.80 |
$34.37M |
$33.48M |
97.4% |
| 2018 |
$-1.88 |
$-49.51M |
$-51.73M |
- |
| 2019 |
$4.85 |
$135.39M |
$133.31M |
98.5% |
| 2020 |
$-2.99 |
$-80.2M |
$-82.06M |
- |
| 2021 |
$2.73 |
$76.94M |
$74.97M |
97.4% |
| 2022 |
$-2.68 |
$-71.62M |
$-73.67M |
- |
| 2023 |
$1.20 |
$34.39M |
$32.8M |
95.4% |
| 2024 |
$0.93 |
$41.74M |
$25.51M |
61.1% |
| 2025 |
$1.79 |
$43.6M |
$49.11M |
112.6% |
